1 2 3 4	Flipped C-Terminal Ends of APOA1 Promote ABCA1-dependent Cholesterol Efflux by Small HDLs
5 6 7 8 9	Yi He, PhD ¹ , Chiara Pavanello, PhD ² , Patrick M. Hutchins, PhD ¹ , Chongren Tang, PhD ¹ , Mohsen Pourmousa, PhD ³ , Tomas Vaisar, PhD ¹ , Hyun D. Song, PhD ⁴ , Richard W. Pastor, PhD ³ , Alan T. Remaley, MD, PhD ⁵ , Ira J. Goldberg, MD ⁶ , Tina Costacou, PhD ⁷ , W. Sean Davidson, PhD ⁸ , Karin E. Bornfeldt, PhD ¹ , Laura Calabresi, PhD ² , Jere P. Segrest, MD ⁴ , and Jay W. Heinecke, MD ¹
10 11 12 13 14 15 16 17 18 19 20 21 22	 ¹Department of Medicine, University of Washington, Seattle, WA, 98109, USA; ²Centro Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy; ³Laboratory of Computational Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892; ⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 37240, USA; ⁵Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892; ⁶Department of Medicine, New York University, New York, NY, 10016, USA; ⁷Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, 15261, USA; ⁸Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45237, USA
23 24	Correspondence : Jay Heinecke, 850 Republican St, Box 358055, UW Medicine, Seattle, WA 98109 USA. E-mail: heinecke@uw.edu
25 26	Keywords : ABCA1, molecular dynamics simulation, cholesterol efflux capacity, chemical crosslinking, peptide analysis
27 28 29 30 31 32 33 34 35	Abbreviations and acronyms: ABCA1, ATP-binding cassette transporter A1; APOA1, apolipoprotein A1; APOB, apolipoprotein B; BHK, baby hamster kidney; calibrated IMA, calibrated ion mobility analysis; CEC, cholesterol efflux capacity; CVD, cardiovascular disease; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; HDL-C, high-density lipoprotein cholesterol; HDL-P, HDL particle concentration determined by calibrated IMA; LCAT, lecithin–cholesterol acyltransferase; LDL-C, low-density lipoprotein cholesterol; L-HDL, large HDL; M-HDL, medium HDL; MS, mass spectrometry; r-HDL, reconstituted HDL; S-HDL, small HDL; XS-HDL, extra small HDL; MD, molecular dynamics.

- 36
- 37

38

Abstract

- 39 Background: Cholesterol efflux capacity (CEC) predicts cardiovascular disease (CVD)
- 40 independently of HDL cholesterol (HDL-C) levels. Isolated small HDL particles are
- 41 potent promoters of macrophage CEC by the ABCA1 pathway, but the underlying
- 42 mechanisms are unclear.
- 43 **Methods**: We used model system studies of reconstituted HDL and plasma from control
- 44 and lecithin-cholesterol acyltransferase (LCAT)-deficient subjects to investigate the
- 45 relationships among the sizes of HDL particles, the structure of APOA1 in the different
- 46 particles, and the CECs of plasma and isolated HDLs.
- 47 **Results**: We quantified macrophage and ABCA1 CEC of four distinct sizes of
- 48 reconstituted HDL (r-HDL). CEC increased as particle size decreased. MS/MS analysis
- 49 of chemically crosslinked peptides and molecular dynamics simulations of APOA1
- 50 (HDL's major protein) indicated that the mobility of that protein's C-terminus was
- 51 markedly higher and flipped off the surface in the smallest particles. To explore the
- 52 physiological relevance of the model system studies, we isolated HDL from LCAT-
- 53 deficient subjects, whose small HDLs–like r-HDLs–are discoidal and composed of
- APOA1, cholesterol, and phospholipid. Despite their very low plasma levels of HDL
- 55 particles, these subjects had normal CEC. In both the LCAT-deficient subjects and
- 56 control subjects, the CEC of isolated extra-small HDL (a mixture of extra-small and 57 small HDL by calibrated ion mobility analysis) was 3–5-fold greater than that of the
- 58 larger sizes of isolated HDL. Incubating LCAT-deficient plasma and control plasma with
- 59 human LCAT converted extra-small and small HDL particles into larger particles, and it
- 60 markedly inhibited CEC.
- 61 **Conclusions:** We present a mechanism for the enhanced CEC of small HDLs. In
- 62 smaller particles, the C-termini of the two antiparallel molecules of APOA1 are flipped
- off the lipid surface of HDL. This extended conformation allows them to engage with
 ABCA1. In contrast, the C-termini of larger HDLs are unable to interact productively with
- 65 ABCA1 because they form a helical bundle that strongly adheres to the lipid on the
- 66 particle. Enhanced CEC, as seen with the smaller particles, predicts decreased CVD
- 67 risk. Thus, extra-small and small HDLs may be key mediators and indicators of HDL's
- 68 cardioprotective effects.
- 69

70

Clinical Perspective (100 words)

- Using chemical crosslinking and molecular dynamics simulations, we showed that
 the C-termini of APOA1, HDL's major protein, have increased mobility and
 conformational freedom in small HDL particles.
- The enhanced mobility of the C-termini of APOA1 in small HDLs allows the C-termini
 to 'flip' off a particle's surface, activating ABCA1 thereby stimulating cholesterol
 removal from cells.
- Because of small HDLs' vital role in cholesterol efflux, quantification of HDL-P (the size and concentration of HDL subspecies) might be a better metric for gauging cardiovascular disease risk than HDL-cholesterol levels.
- Therapeutic interventions that increase small HDL levels, with or without increasing
- 81 HDL-cholesterol levels, may be cardioprotective.

82

Introduction

83 The risk of cardiovascular disease (CVD) strongly and inversely associates with plasma

84 levels of high-density lipoprotein cholesterol (HDL-C).¹ However, pharmacological

85 interventions that elevate HDL-C have failed to lower CVD risk in statin-treated subjects,

suggesting that the association between HDL-C and CVD risk is indirect.² It is therefore

87 critical to identify new mechanisms that inversely link HDL to CVD risk and do not

88 involve HDL-C.^{3,4}

89 One proposed cardioprotective function of HDL is promotion of cholesterol efflux from

90 lipid-laden macrophages, which play critical roles in all stages of atherogenesis.⁵ Two

91 early steps in this pathway involve ATP-binding cassette transporters—ABCA1 and

ABCG1. Initially, ABCA1 mediates cholesterol efflux from macrophages to lipid-poor
 apolipoproteins⁶ and small dense HDL.^{7,8} Lecithin-cholesterol acyltransferase (LCAT)

94 then promotes HDL maturation by catalyzing the conversion of free cholesterol to

95 cholesteryl esters, which are then transferred from the surface to the core, generating

96 larger HDL particles.⁹ ABCG1 exports cellular cholesterol to larger HDL particles that

97 deliver cholesterol to the liver for excretion in bile.²

98 Rothblat, Rader, and colleagues demonstrated that serum HDL (serum depleted of

99 lipoproteins that contain apolipoprotein B [APOB]) promotes cholesterol efflux from

- 100 cultured macrophages, thus mimicking the key early steps in reverse cholesterol
- transport from macrophages.^{10,11} The magnitude of cholesterol efflux to serum HDL,
- 102 termed cholesterol efflux capacity (CEC), is largely independent of HDL-C.^{10,11}

103 However, large clinical studies demonstrate that macrophage CEC and ABCA1-specific

- 104 CEC of serum HDL strongly and negatively associate with prevalent and incident
- 105 CVD.¹² Importantly, CEC predicts CVD independently of HDL-C.¹¹⁻¹³ These results
- 106 suggest that CEC is a critical contributor to HDL's proposed anti-atherogenic functions 107 in humans.
- 108 Lecithin-cholesterol acyltransferase (LCAT) is widely regarded as an important driving
- 109 force for mobilizing cholesterol from tissues to the liver for excretion. However, subjects
- 110 with complete LCAT deficiency do not appear to be at increased risk for CVD¹⁴ despite
- 111 having very low HDL-C levels. Animal models of atherosclerosis have yielded conflicting
- 112 results on the impact of LCAT deficiency and overexpression.^{15,16} Serum from LCAT-
- 113 deficient subjects exhibits elevated ABCA1-dependent cellular cholesterol efflux even
- 114 though efflux via ABCG1 and SR-B1 is impaired, suggesting that cholesterol efflux by
- 115 the ABCA1 pathway might explain why those subjects are not at high risk for CVD.¹⁷
- 116 CSL-112, a reconstituted HDL particle composed of human APOA1 and
- 117 phosphatidylcholine, was designed to mimic small HDLs.¹⁸ The drug, which markedly
- enhances the ABCA1 CEC of human plasma, promotes the remodeling of HDL resulting
- 119 in higher levels of small and lipid-poor APOA1 particles.¹⁹
- 120 Small HDLs account for most of serum HDL's CEC activity.^{7,8} However, the underlying
- mechanisms are poorly understood. To explore potential mechanisms, we combined
- functional and structural studies of reconstituted HDL particles (r-HDL) with studies of
- 123 control and LCAT-deficient subjects. Our studies reveal that the C-terminus of APOA1
- in smaller HDLs becomes available to engage ABCA1, the first key step in cholesterol
- 125 export from cells.

- 126
- 127

128

Experimental Methods

- 129 Generation of reconstituted HDL (r-HDL) particles. Discoidal r-HDL was prepared
- 130 from recombinant human APOA1, 1-palmitoyl-oleoyl-phosphatidylcholine (POPC), and
- free cholesterol by cholate dialysis.²⁰⁻²² The composition of the different size of particles
- 132 are (APOA1: free cholesterol: POPC, mol/mol): r-HDL-80, 1.0:1.8:34; r-HDL-88, 1.0:2.0:52.7; r-HDL-96, 1.0:4.7:00.6; r-HDL, 120, 1.0:4.7:140.22
- 133 1.0:2.9:52.7; r-HDL-96, 1.0:4.7:90.6; r-HDL-120, 1.0:4.7:140.²²
- 134 **Calibrated ion mobility analysis (IMA).** The sizes of r-HDL and human HDL particles
- were quantified with a scanning mobility particle sizer spectrometer (TSI Inc.,
- Shoreview, MN, model 3080N).²³⁻²⁵ The concentrations of r-HDL and HDL particles
 (mol/L) were determined using a calibration curve of glucose oxidase.²³
- 139 *Chemical crosslinking of r-HDL.* Reconstituted HDLs (r-HDLs) were crosslinked with
- 140 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) in phosphate-
- 141 buffered saline (pH 6.5),^{20,26} and further fractionated by high-resolution size exclusion
- 142 chromatography to isolate monomeric HDL particles. Details are provided in
- 143 Supplemental Material.
- Proteolytic digestion and mass spectrometry analysis. Details are provided in
 Supplemental Material.
- 146 Molecular dynamics simulations of r-HDL. Molecular dynamics (MD) trajectories of r-
- 147 HDL-80 and r-HDL-90 were calculated using a combination of all-atom simulation,
- simulated tempering, and coarse-grained (CG) methods (Supplemental Material).²⁷⁻³⁰
- 149 Simulations of r-HDL-100 and r-HDL-120 (termed r-HDL-110) were reported
- 150 previously.²⁷ Because different preparations of the largest r-HDL particles range in size
- 151 from 110–120 Å,²² we term these r-HDL-120 to be consistent with the size of the largest
- 152 particles used here.
- HDL contact map analyses. Inter- and intramolecular contact maps between Cα atoms used a cutoff distance of 15.1 Å.²⁷ A total of 2,084 and 1,042 frames from the last half of
- 155 20 μ s and 10 μ s simulations were used for the r-HDL-100 and r-HDL-120 particles,
- 156 respectively.²⁷ A total of 100 frames extracted from the last half of 200 μ s CG
- 157 simulations of r-HDL-80 and r-HDL-90 particles were converted to all-atom structures to
- 158 develop the contact maps. Contact maps were plotted using Gnuplot version 5.2 (http://gnuplot.info)
- 159 (http://gnuplot.info).
- 160 *Cholesterol efflux capacity (CEC).* Macrophage cholesterol efflux capacity was
- assessed with J774 macrophages labeled with [³H]cholesterol and stimulated with a
- 162 cAMP analog.¹⁰ Efflux via the ABCA1 pathway was measured with baby hamster kidney
- 163 (BHK) cells that expressed mifepristone-inducible human ABCA1 and were labeled with
- 164 [³H]cholesterol.⁶
- 165 *LCAT-deficient and control subjects.* Twenty-four subjects; 4 carriers of two mutant
- 166 LCAT alleles (termed LCAT-/- subjects), 6 carriers of 1 mutant LCAT allele (LCAT+/-),
- and 14 non-carriers (LCAT+/+) were from an Italian family study. The Italian LCAT
- 168 deficient cohort includes related carriers (**Supplemental Table S1**). The study was

- approved by the institutional ethical committee.³¹ All subjects gave informed consent.
- 170 Aliquots of serum from subjects who had fasted overnight were immediately frozen and
- 171 stored at -80°C until analysis. Serum lipid levels and LCAT activity of the Italian cohort
- 172 were determined as described.³¹
- 173 *Incubation of control and LCAT-deficient plasma with LCAT*. Details are provided in
 174 Supplemental Material.³²
- 175 HDL Isolation. For functional studies, HDL was first isolated by ultracentrifugation
- 176 (density 1.063–1.210 g/mL)³³ from serum of control subjects (n=4) and LCAT-/- subjects
- 177 (n=5) and then fractionated on a Superdex 200 Increase 10/300 GL column. Details are
- 178 provided in Supplemental Material.
- 179 *Data availability*. All data supporting the findings of this study are available in the180 article and/or its supplemental materials.
- 181 Statistical Analyses. Statistical analyses were performed with STATA software version
- 182 12 (Stata Corp, College Park, TX) and with SAS v.9.4 (SAS Inc, Cary, NC, USA). Mixed
- effect models, considering family as a random effect, with Tukey-Kramer post-hoc tests
- 184 were used to compare the means of three or more groups. One-way ANOVA was used 185 to analyze laboratory experiments. Linear regression was used to investigate the
- 186 correlation of serum HDL CEC with HDL particle concentration for each subspecies.
- 187 Parametric or non-parametric analyses were based on the Shapiro-Wilk test for
- 188 normality. The ratio t-test (GraphPad) was used for the analysis of plasma incubations
- 189 with/without LCAT. The null hypothesis is that the average of the logarithms of the ratio
- 190 of each pair is zero. *P*-values < 0.05 were considered significant. Unless otherwise
- 190 of each pair is zero. *P*-values <0.05 were considered significant. Onless our 191 stated, values represent means ± standard deviations.
- 192

Results

193 Reconstituted small HDL particles promote macrophage CEC and ABCA1 CEC as 194 effectively as lipid-free APOA1.

- 195 We used reconstituted discoidal HDL (r-HDL) as a model system to investigate how
- 196 particle size affects HDL's ability to promote CEC.^{20,22} To quantify cholesterol efflux by
- 197 macrophages and the ABCA1 pathway, we used validated model systems.^{8,10,11} r-HDLs
- 198 were fractionated into 4 different sizes of particles, using high-resolution size exclusion
- 199 chromatography.²⁰ We term these particles r-HDL-80, r-HDL-88, r-HDL-96, and r-HDL-
- 200 120 because their diameters are respectively 80 Å, 88 Å, 96 Å, and 110-120 Å as
- determined by calibrated IMA (**Fig. 1A**). These values are in excellent agreement with
- 202 those previously determined by non-denaturing gradient gel electrophoresis and by
- 203 quantification of the hydrodynamic Stokes' diameters of the particles.²²
- 204 Each particle population exhibited a symmetrical Gaussian-like distribution and was
- clearly distinguishable from the other sizes of particles by IMA (Fig. 1A). The r-HDL
 particles were similar in size to human XS-HDL, S-HDL, M-HDL, and L-HDL (see
- 200 particles were 207 below).
- 208 At equimolar concentrations, the smallest r-HDL-80 particles were as effective as lipid-
- 209 free APOA1 at promoting both macrophage CEC and ABCA1 CEC (Fig. 1B). The r-
- 210 HDL-88 particles were less effective, and the two largest r-HDL particles (r-HDL-96 and
- r-HDL-120) failed to promote either macrophage CEC or ABCA1 CEC.

212 **Probing the structure of APOA1 in r-HDLs with MS/MS**

213 In their double belt model for HDL, Segrest et al.³⁴ proposed that 2 molecules of APOA1

- form an anti-parallel helical bundle that encircles the edge of the discoidal HDL particle.
- 215 The crystal structure of N-terminally truncated APOA1³⁵ and chemical crosslinking
- studies of r-HDL^{20,27,36} and human HDL²⁰ support this model.

217 In contrast to APOA1's central region, which forms a stable helical bundle, the N- and

- 218 C-terminal regions of APOA1 in HDL are more flexible and capable of assuming a
- 219 variety of conformations.^{22,27,36,37} These regions of the protein are also important for
- promoting ABCA1-dependent cholesterol efflux.³⁶ To investigate the structures of the different regions of APOA1 in the different sizes of r-HDL, we used EDC (1-ethyl-3-(3-
- dimeter regions of AFOAT in the dimeter sizes of FHDL, we used EDC (Fetry-3-(3-222 dimethylaminopropyl)carbodiimide hydrochloride)²⁰ to generate intramolecular and
- intermolecular zero-order crosslinks in APOA1. EDC reacts with the amino group of
- lysine resides that are close to the carboxylic acid group of aspartate and glutamate to
- form an amide bond. Thus, EDC crosslinks identify salt bridges in structures. The
- 226 crosslinked r-HDLs were reisolated by high-resolution size exclusion chromatography to
- 227 eliminate HDL particles that were crosslinked to each other. Importantly, all crosslinking
- reactions were carried out at low concentrations of EDC in phosphate-buffered normal
- saline at pH 6.5, which more closely mimics physiological conditions than those used to crystallize proteins.
- 231 After the crosslinked APOA1 was digested, the resulting peptide mixture was
- fractionated by capillary liquid chromatography and analyzed by tandem MS/MS. To
- distinguish between inter- and intramolecular crosslinks of APOA1 in r-HDL, we used a
- 1:1 mixture of human [14 N]APOA1 (light, L) and [15 N]APOA1 (heavy, H) (isotopic
- 235 purity >99%) to generate the particles.^{20,38} Three combinations of crosslinks are
- possible: L-L, L-H, and H-H. The L and H forms of APOA1 are chemically identical but
- differ in molecular mass, making intramolecular and intermolecular crosslinks readily
- distinguishable in MS1 scans. For intra-protein crosslinks, where the protein is linked to
- itself, only L-L and H-H forms are detected (relative abundance ~1:1). For inter-protein
- crosslinks, LL, L-H, and H-H peptides are detected (relative abundance ~1:2:1)
- 241 (Supplemental Material, Fig. S1 and S2).^{20,38}

242 Different sizes of r-HDL exhibit distinct patterns of intramolecular and

intermolecular crosslinks between peptides in the N-terminal and C-terminal regions of APOA1.

- 245 This approach identified 34 intramolecular and 31 intermolecular crosslinks in the four
- sizes of r-HDL (**Supplemental Material, Table S2**). Similar numbers of intramolecular
- crosslinks were detected in the three largest particles (r-HDL-120, 8 crosslinks; r-HDL-
- 248 96, 6 crosslinks; r-HDL-88, 7 crosslinks). In contrast, we identified twice as many
- 249 intramolecular crosslinks in the r-HDL-80 particle (13 crosslinks). These observations
- 250 indicate that APOA1 has greater conformational freedom in the smallest r-HDL particles
- than in the other sizes of HDL.

Probing the behavior of HDL particles over time with molecular dynamicsimulations

- 254 To investigate how APOA1 conformation and mobility vary in the different sizes of r-
- HDL, we used a computational method called molecular dynamics (MD). Here

trajectories of systems modeling r-HDL (2 APOA1 bound to a nanodisc composed of
POPC and ~10% cholesterol, and surrounded by water) are generated for multiple
microseconds. The result is a series of snapshots of the dynamic evolution for all of the
atoms in the system.

We previously used this approach to generate trajectories of r-HDL-100 and r-HDL-120 particles (100 Å and 120 Å diameter particles, Supplemental Material).²⁷ To generate the double belt models for r-HDL-80 and r-HDL-90 particles (80 Å and 90 Å diameter particles), we ran MD simulations after removing cholesterol and POPC from the computer generated r-HDL-100 particle (Supplemental Material). We then determined whether the crosslinks we identified in APOA1 in the different sizes of r-HDL were consistent with the double belt model.³⁴

- To perform this analysis, we compared inter- and intramolecular distances between Cα
 atoms in the models, using an HDL contact map to plot a detected peptide by the
 position of its two amino acids in APOA1's sequence. The maximum distance between
- 270 the backbone $C\alpha$ atoms of amino acids in the crosslinked peptides is the sum of the
- length of two side chains plus the length of the amide bond formed by EDC (10.5 Å for
- K-D linkage and 12.1 Å for K-E). **Fig. 2** shows the position of each crosslink in the
- contact maps for the simulated belt structure for each size of HDL. The cutoff radius for the crosslink residing in the double belt model was 15.1 Å (12.1 Å for the K–D crosslink
- 275 plus a 3 Å motion averaging factor).²⁷
- 276 Only one of the crosslinks detected in the largest particle (r-HDL-120) was inconsistent 277 with the double belt model of HDL (Fig. 2A; intermolecular crosslinks, red regions; 278 intramolecular crosslinks, green regions). Just two of the crosslinks in the r-HDL-100 279 particle were inconsistent (Fig. 2B). In contrast, 7 and 9 crosslinks in the r-HDL-90 and 280 r-HDL-80 particles were inconsistent with the prototypical double belt model. In r-HDL-281 90, four of the 7 crosslinks were in the C-terminus of APOA1; in r-HDL-80, six of the 9 282 crosslinks were in the C-terminus (Fig. 2C-D). The large number of crosslinks in the C-283 terminus of the two smallest particles (r-HDL-90 and r-HDL-80) indicates that this region 284 is more loosely organized than in the larger particles and thus underwent a larger 285 number of cross-linking reactions in the experiment.
- These observations indicate that the central region of the APOA1 dimer is organized as a double belt in all the sizes of r-HDL we studied. In contrast, the N-terminal and Cterminal regions differ according to particle size. Specifically, the C-termini of APOA1 are markedly more mobile in the two smallest particles. Many of the observed crosslinks in the N-termini of APOA1 of the three smallest HDLs also fell outside the contact zones predicted by the double belt model (**Fig. 2B-D**), which is consistent with the proposal that the N-terminus APOA1 in r-HDL-100 is hinged.²⁷

293The C-termini of small HDL particles exhibit greater mobility than those of large294HDL particles.

Figure 3A-H illustrates the conformational states of APOA1 obtained by MD simulations of the HDL particles of varying sizes, with lipids and water excluded from the image for clarity. In the case of r-HDL-120 particles, the two proteins adopt a predominantly double-belt arrangement, although some displacement of the C-terminal helices (H10A and B) occurs.²⁷ Disorder in the N-terminal region (residues 1-43) is noticeable in r-

300 HDL-100 particles, and both the N- and C-termini lose their double-belt characteristics

- in r-HDL-90 particles. Both C-termini are flipped off the lipid edge in the r-HDL-90 particles (**Fig. 3E,F**).
- 303 The structure of the smallest particle, r-HDL-80, markedly differs from that of the larger
- 304 r-HDL particles. The smallest particles are shaped like a spherical micelle, deviating
- 305 from the disk-like structure, and the double-belt arrangement is largely absent except for
- helix 5 (green) (**Fig. 3G,H**). There is also significant unwinding and displacement of the
- 307 C-terminal helices.
- 308 It is important to note that the images (**Fig. 3**) represent snapshots of individual
- 309 simulations at specific time points and do not capture the complete flexibility of the
- terminal helices. Although the simulations of the large r-HDL-100 and r-HDL-120
- 311 particles show that the C-termini remain associated with the lipid surface, they could
- detach in the presence of a protein such as ABCA1. Thus, these images represent low
- energy states but not the sole states achievable by these systems.²⁸ It is also worth
- noting that the time scale, potential energy functions, and restraints employed in the all-
- atom and coarse-grained simulations tend to maintain the helical structure of the protein
- 316 residues.

317 Clinical characteristics of LCAT-deficient and control subjects.

- Like the reconstituted HDL particles used in our model system studies, the extra-small and small HDL particles in LCAT-deficient subjects are discoidal and composed largely of APOA1, free cholesterol, and phospholipid.^{39,40} We therefore used serum HDL and
- HDLs isolated from control and LCAT-deficient subjects to investigate the relevance of our model system studies to human HDL.
- 323 We studied three groups of subjects: 14 controls, 6 subjects with heterozygous LCAT
- deficiency (LCAT+/-), and 6 with LCAT deficiency (LCAT-/-).³¹ Two of the LCAT-/-
- 325 subjects were unrelated to the subjects in the family study. The three groups had similar
- ages, percentages of females, and plasma LDL-C levels (**Table 1**). Compared to the
- 327 LCAT+/+ subjects, the LCAT+/- subjects had significantly lower plasma HDL-C levels,
- 328 as did the LCAT-/- subjects (*P*=0.0005). Plasma triglyceride levels were not significantly
- 329 different between the groups (P=0.28; Mixed effect model and Tukey-Kramer post-
- tests). LCAT activity was undetectable in the LCAT-/- subjects (0 nmol/mL per h), with significantly higher levels in the LCAT+/- subjects and LCAT+/+ subjects (P<0.0001)
- 331 significantly higher levels in the LCAT+/- subjects and LCAT+/+ subjects (*P*<0.0001).

Extra-small HDL (XS-HDL) and small HDL (S-HDL) particles are enriched in LCAT deficient subjects.

- 334 We used calibrated IMA to quantify total HDL (Total HDL) and four sizes of HDL
- particles: extra-small HDL (XS-HDL), small HDL (S-HDL), medium HDL (M-HDL), and
- arge HDL (L-HDL) (**Fig. 4A; Supplemental Material, Table S3**). This method for
- 337 quantifying HDL-P yields a stoichiometry of APOA1 and sizes and relative abundances
- of HDL subspecies that agree well with those determined by non-denaturing gradient
 gel electrophoresis and analytical ultracentrifugation.^{23,41} In the LCAT+/+ subjects, M-
- 339 get electrophoresis and analytical ultracentritugation.^{29,44} In the LCAT+/+ SUBJECTS, 340 HDL (mean diameter 0.2+0.1 nm) was the meet abundant particle perturbing it.
- HDL (mean diameter, 9.2±0.1 nm) was the most abundant particle population; it
 accounted for ~50% of total HDL (Fig. 4A). All four sizes of HDL were detected in all the
- 342 control subjects. In contrast, subjects with partial LCAT deficiency had elevated levels of

- 343 XS-HDL (mean diameter, 7.8±0.1 nm) and S-HDL (mean diameter, 8.4±0.1 nm
- diameter) particles (**Fig. 4A**). Subjects with complete LCAT deficiency exhibited only
- 345 XS-HDL (**Fig. 4A**).

346 The total concentration of HDL particles and the distribution of the different sizes of HDL

- also differed significantly among the three groups (**Fig. 4B-F**; **Supplemental Material**,
- **Table S3**). Mean Total-HDL-P levels in control subjects were 5.1 times higher than
- those in LCAT-/- subjects and 1.8 times higher than those in LCAT+/- subjects
- 350 (*P*<0.0001). This reflected significantly lower levels of both M-HDL and L-HDL in
- 351 subjects with complete or partial LCAT deficiency (P<0.0001 for both M-HDL and L-
- 352 HDL). In contrast, mean levels of XS-HDL were higher in both LCAT-/- and LCAT+/-
- subjects than in control subjects. LCAT-/- and LCAT+/- subjects had similar levels of
 XS-HDL and L-HDL.

355 Serum HDL from LCAT-deficient subjects has normal macrophage and ABCA1 356 cholesterol efflux capacity despite low total HDL-P.

- 357 We used serum HDL (APOB-depleted serum) to quantify the subjects' CEC, as
- described by Rothblat et al.^{10,11} Macrophage and ABCA1 CEC were evaluated using J774 macrophages stimulated with cAMP or BHK cells with mifepristone-inducible
- acceleration and the second se
- and without induction of ABCA1, was a linear function of serum HDL concentration and
 incubation time. A mixed effect model demonstrated that macrophage CEC and ABCA1
- 363 CEC did not differ significantly between LCAT-/- and control subjects (P>0.3).
- 364 To begin to identify the HDL subpopulations that drive macrophage CEC and ABCA1
- CEC, we correlated the CEC of serum HDL with the particle concentration of each HDL subpopulation from all the study subjects (**Supplemental Fig. S3**). Macrophage CEC only correlated positively and strongly with the concentration of XS-HDL particle concentration (r=0.55, *P*=0.004). These observations suggest that XS-HDL is an important driver of cellular cholesterol export from both macrophages and through the ABCA1 pathway.

371 Small and extra-small HDL particles are the major promoters of macrophage CEC 372 and ABCA1 CEC in both LCAT-deficient subjects and control subjects.

- 373 To further investigate how XS-HDL promotes CEC, we used ultracentrifugation and
- 374 high-resolution size exclusion chromatography to isolate XS-HDL from LCAT-/-
- 375 subjects. We then compared the CEC activity of XS-HDL with that of four sizes of HDL
- 376 isolated from LCAT +/+ subjects. The mean diameters of the isolated HDLs were 8.4
- 377 nm, 8.8 nm, 9.2 nm, and 14 nm (**Fig. 5A**; size distributions), respectively.
- We quantified macrophage and ABCA1 CEC as described above for serum HDL.
- 379 Importantly, we incubated the cells with equimolar concentrations of isolated particles of
- ach size of HDL. CEC was a linear function of HDL particle concentration and the
- 381 incubation time used in the assays. XS-HDL isolated from LCAT-/- subjects, composed
- almost exclusively of 7.8 nm diameter particles (XS-HDL-sized), strongly promoted both
- 383 macrophage and ABCA1 CEC. However, it was less potent than 8.4 nm XS-HDL
- particles isolated from LCAT +/+ subjects (**Fig. 5B**), which were composed of
- 385 approximately equimolar amounts of XS-HDL and S-HDL (as determined by calibrated

IMA). On a molar basis, 8.4 nm HDL isolated from control subjects was as effective as
 lipid-free APOA1 in promoting both macrophage CEC and ABCA1 CEC. On a molar

388 basis, XS-HDL isolated from LCAT-/- subjects promoted macrophage CEC much more

effectively than 8.8 nm HDL, 9.2 nm HDL, or 14 nm HDL isolated from control subjects,

and the differences were significant (P=0.0002 for 8.8 nm HDL, P<0.0001 for 9.2 nm

391 HDL, and *P*<0.0001 for 14 nm HDL). We obtained similar results when we determined

how effectively the different sizes of isolated HDL promoted ABCA1 CEC (**Fig. 5C**).

393 LCAT converts small HDLs into large HDLs, markedly reducing CEC.

- 394 To test the hypothesis that LCAT is one important factor controlling the CEC of
- 395 circulating HDL, we incubated control plasma and LCAT-deficient plasma with or
- 396 without recombinant human LCAT at 37°C for 2 h, stopped the LCAT reaction with
- 397 DTNB, and quantified ABCA1 CEC and HDL-P, using calibrated IMA. Control
- 398 experiments demonstrated that DTNB had no impact on quantification of ABCA1 CEC.
- 399 Before incubation with LCAT, the major HDL species in the LCAT-/- subjects was XS-
- 400 HDL. In contrast, all 4 sizes of HDL were observed in the control subjects; M-HDL was
- 401 the most abundant species. LCAT treatment decreased the ABCA1 CEC of both control

402 plasma and LCAT-/- plasma by ~50% (Fig. 6A). LCAT converted virtually all XS-HDL

403 and most S-HDL particles into larger HDLs in plasma of both control and LCAT-deficient

- 404 subjects (**Fig. 6B**). In plasma treated with LCAT, free cholesterol markedly decreased
- 405 while total cholesterol did not change significantly (**Fig 6C-D**).
- 406 Collectively, these observations support the proposal that small HDLs are the major
- 407 HDL species promoting both ABCA1 and macrophage CEC.
- 408

Discussion

To investigate the mechanisms that regulate HDL's ability to promote cholesterol efflux by the ABCA1 pathway, we quantified the CEC of four different sizes of r-HDLs. As with

human HDL,^{7,8} the smallest r-HDL particles were the strongest promoters of cholesterol
 efflux. Chemical crosslinking followed by MS/MS analysis showed that twice as many

- efflux. Chemical crosslinking followed by MS/MS analysis showed that twice as many
 intramolecular crosslinked peptides had formed in the smallest r-HDL than in the three
- 414 larger sizes, indicating that APOA1 had markedly higher mobility. When we plotted the
- 415 positions of the chemically crosslinked peptides on an HDL contact map, virtually all the
- 416 peptides detected in the two largest r-HDL particles were consistent with molecular
- 417 dynamics simulations of the double belt model of APOA1. In this model, the helical
- 418 repeats of two APOA1 molecules assume an anti-parallel helical structure that forms a
- 419 bundle surrounding the edges of discoidal HDL. Because the helical bundle is
- 420 amphipathic and has high lipid affinity,⁴² these observations strongly suggest that most
- 421 of the APOA1 in the two largest HDL particles is bound to lipid and therefore would not
- 422 be accessible to ABCA1.
- 423 The two smallest HDL particles showed a different pattern of chemically crosslinked
- 424 peptides: the peptides of APOA1's central region were consistent with the double belt
- 425 model, but those at the C-terminus were not (i.e., the C-termini in the APOA1 dimer are
- 426 not in a helical bundle). Moreover, the smallest HDL had the largest number of
- 427 detectable chemically crosslinked peptides in the C-terminus of APOA1. Taken
- 428 together, these data indicate that the C-terminus of APOA1 in the small HDL particles

429 have enhanced conformational mobility, likely due to a loss of overall helicity. Because

lipid interaction is a major driver of helical formation in APOA1, it is conceivable that the

431 C-terminus is detached from the lipid surface in the two smallest r-HDLs as observed in

432 the MD simulations of those particles.

433 The C-terminus of APOA1 plays a critical role in promoting cholesterol export by 434 ABCA1.⁴²⁻⁴⁴ We envision two factors that drive its increased mobility and loss of helical 435 structure in small HDLs. First, crowding, as small HDL's limited surface area might not 436 accommodate all of APOA1's helices, preventing the C-termini of APOA1 from lying on 437 the particle's surface. Second, extreme surface curvature, which could prevent 438 APOA1's C-terminal domain from fully interacting with lipid because it cannot turn 439 sharply enough to lie down on the surface. In this model, the two antiparallel C-termini 440 are "flipped" off the surface of smaller HDLs (Fig. 7), where their increased mobility and 441 freedom from lipid binding promote their engagement with ABCA1. In contrast, the C-442 termini of larger HDLs are strongly bound to lipid and unable to interact productively 443 with ABCA1. On a molar basis, the smallest r-HDL and human HDL particles were as 444 efficient at promoting cholesterol efflux by the ABCA1 pathway as was lipid-free

445 APOA1, which is consistent with this model.

446 We suggest that the smaller, less lipidated HDL particles may not be fully "filled" with

447 lipid and remain effective substrates for ABCA1. At some point between diameters of 80

448 and 90 Å, the APOA1 C-terminus finds room to associate with the surface of the

particle, shutting down additional lipid accumulation by ABCA1 and possibly promoting

the release of a more 'mature' particle. In this scheme, the APOA1 C-terminus functions

as a lipid level switch that defines the maximal size of HDL particles formed by ABCA1.

An alternative hypothesis for the role of the C-terminus of APOA1 in promoting CEC is
that it involves binding of the protein to phospholipid-rich domains in the plasma
membrane of cells,^{45,46} which in turn promotes phospholipid and cholesterol efflux.
Consistent with this, deletion of helices H8-H10 decreases binding to lipid vesicles but
has little impact on cross-linking of radiolabeled APOA1 to ABCA1 on cells. However,
our recent studies⁴⁷ suggest that the lipid-affinity of APOA1 plays a role in promoting the
movement of phospholipids from the outer-leaflet of the plasma membrane into a

459 hydrophobic tunnel in the interior of the extracellular domain of ABCA1.

460 To test the relevance of our model system studies to human HDL, we used serum HDL 461 and HDL isolated from LCAT-deficient carriers. Like r-HDLs, the latter is discoidal and 462 composed of APOA1, free cholesterol, and phospholipid. We found that total HDL 463 particle concentration was markedly lower in subjects who completely lacked LCAT 464 activity. The major HDL subspecies in those subjects was XS-HDL, which is very similar 465 in size (78 Å in diameter) to the smallest r-HDL-80 particles used in our model system 466 studies (80 Å). In subjects who were only partially LCAT-deficient, the major HDL 467 subspecies were XS-HDL and S-HDL. In subjects with normal LCAT activity, we 468 detected all four sizes of HDL; M-HDL was the major species. Even though serum from 469 the LCAT-deficient subjects had very low HDL particle concentrations, ABCA1 CEC and 470 macrophage CEC were similar to that of the controls, strongly suggesting that the 471 ABCA1-specific activities of extra-small and small HDL were greater than those of the 472 larger HDL particles. Consistent with this proposal, macrophage and ABCA1 CEC

473 strongly and positively correlated with the concentration of XS-HDL in plasma.

474 To confirm these ideas, we used isolated HDL from subjects with and without complete 475 LCAT deficiency. Then we determined macrophage and ABCA1 CEC activity at equal 476 particle concentrations. The isolated particles had diameters of 8.4 nm, 8.8 nm, 9.2 nm, 477 and 14 nm-very similar to the sizes of XS-HDL, S-HDL, M-HDL, and L-HDL in plasma 478 as guantified by calibrated IMA. It is important to note that the isolated HDLs did not 479 precisely mimic the size distributions of the HDL subclasses in plasma from the LCAT-480 deficient and control subjects. Extra-small HDL isolated from control subjects, which 481 was a mixture of XS-HDL and S-HDL, had the highest macrophage and ABCA1 CEC 482 specific activities; they were about 4–5-fold greater than those of the three larger sizes 483 of isolated HDL. XS-HDL isolated from the LCAT-deficient subjects did not contain S-484 HDL and was less active than XS-HDL isolated from the control subjects; macrophage 485 CEC and ABCA1 CEC of the isolated HDLs were ~3-fold greater than for the larger 486 sizes of HDL. Lipid-free APOA1 was not detectable in the HDL used for these studies 487 because the particles were isolated by both ultracentrifugation and high-resolution size 488 exclusion chromatography.

489 These data suggest that both XS-HDL and S-HDL are the major contributors to

490 macrophage and ABCA1 CEC. This hypothesis is strongly supported by the

demonstration that incubating control plasma and LCAT-deficient plasma with LCAT

492 converted small HDLs into large HDLs and markedly diminished ABCA1 CEC. These
 493 observations are remarkably concordant with animal studies, which demonstrated that

494 ABCA1 CEC of plasma HDL was increased in LCAT-/- and LCAT +/- mice.¹⁶ Moreover,

495 over-expression of LCAT significantly reduced macrophage cholesterol efflux by

496 plasma. Taken together, these observations suggest that XS-HDL and S-HDL, which

497 typically represent 20%-30% of total HDL, are key mediators of ABCA1 CEC and

498 perhaps cardioprotection.

CSL-112, a reconstituted HDL particle that promotes the formation of small and lipid poor APOA1 particles,^{18,19} is being tested in a large, randomized study to determine if it
 reduces the risk of CVD events in post-MI patients. The demonstration that CLS-112
 lowers incident CVD would strongly support the proposal that small HDLs are critical in
 cardioprotection in humans.

504 Our demonstration that small and extra-small HDL particles potently promote

505 cholesterol efflux from macrophages raises the possibility that increased LCAT activity,

506 which converts smaller HDL particles into larger, cholesteryl ester-rich particles, is a risk

507 factor for atherosclerosis.⁴⁸ Consistent with this suggestion, overexpression of LCAT in

508 mice failed to increase reverse cholesterol transport from macrophages to bile.¹⁶ Serum

509 HDL from mice that overexpressed LCAT were less able to promote cholesterol efflux

510 from macrophages by the ABCA1 pathway than control mice.¹⁶ However, studies of the

511 relationships of LCAT to CVD risk in humans have yielded mixed results.^{49,50}

512 One limitation of our investigations is the small number of subjects in our study of LCAT

513 deficiency. However, the large differences in the concentrations of the various sizes of

514 HDL in the different groups of subjects and the consistency of the results with serum

515 HDL and isolated HDL strongly support the proposal that XS-HDL and S-HDL promote

516 cholesterol efflux from macrophages by the ABCA1 pathway. Another limitation is that

517 the size distributions of the isolated HDLs overlapped to some degree, reflecting the

518 limited resolution of size-exclusion chromatography. Nonetheless, the mean sizes of the

isolated HDLs were well separated, and the particle distributions were clearly distinctfrom one another.

521 In summary, both our experiments and molecular dynamics simulations support the 522 proposal that small HDL particles are potent ligands for promoting cholesterol efflux

- from macrophages by the ABCA1 pathway. In future studies, it will clearly be important
- 524 to determine whether XS-HDL and S-HDL predict CVD risk in humans, if LCAT mass
- 525 and/or activity associate with HDL size, and if risk prediction is independent of HDL-C.
- 526
- 527

528 **Acknowledgments.** We thank Dr. Priska von Haller and the Proteomics Resource 529 (UWPR95794, University of Washington) for technical support and Dr. Fabrizio Veglia 530 for statistical advice. Molecular dynamics simulations were performed at the National 531 Institutes of Health (NIH), Bethesda, MD (BIOWULF and Lobos clusters) and on the 532 Anton2 supercomputer. Access to Anton 2 was generously provided by D.E. Shaw 533 Research.

- 534
- 535 **Data availability**. The authors confirm that the data supporting the findings of this study 536 are available within the article and/or its supplementary materials.

537
538 Sources of Funding. This work was supported by awards from the NIH: T32HL007828,
539 R01HL149685, R35HL150754, P01HL151328, P01HL128203, P30DK017047,
540 R01HL153118, R01HL155601, R01HL144558, and R01HL149685; the American Heart
541 Association (15POST22700033); and the Intramural Program of the National Heart
542 Lung and Blood Institute of the NIH. Anton 2 time was provided by the Pittsburgh
543 Supercomputing Center (NIH R01GM116961).

- 543 544
- 545 **Disclosures.** K.E.B. serves on the Scientific Advisory Board of Esperion Therapeutics.
- 546 547

- References
- 548 1. Gordon DJ and Rifkind BM. High-density lipoprotein--the clinical implications of 549 recent studies. *N Engl J Med*. 1989;321:1311-6.
- 550 2. Rader DJ and Hovingh GK. HDL and cardiovascular disease. *Lancet*. 551 2014;384:618-625.
- 552 3. Rader DJ and Tall AR. The not-so-simple HDL story: Is it time to revise the HDL 553 cholesterol hypothesis? *Nat Med*. 2012;18:1344-6.
- 4. Heinecke J. HDL and cardiovascular-disease risk--time for a new approach? *N Engl J Med*. 2011;364:170-1.
- 556 5. Rader DJ, Alexander ET, Weibel GL, Billheimer J and Rothblat GH. The role of 557 reverse cholesterol transport in animals and humans and relationship to atherosclerosis. 558 *J Lipid Res.* 2009;50 Suppl:S189-94.
- 559 6. Oram JF and Heinecke JW. ATP-binding cassette transporter A1: a cell
- 560 cholesterol exporter that protects against cardiovascular disease. *Physiol Rev.* 561 2005;85:1343-72.

562 7. Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK,
563 Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L and
564 Jessup W. HDL particle size is a critical determinant of ABCA1-mediated macrophage
565 cellular cholesterol export. *Circ Res.* 2015;116:1133-42.

He Y, Ronsein GE, Tang C, Jarvik GP, Davidson WS, Kothari V, Song HD,
 Segrest JP, Bornfeldt KE and Heinecke JW. Diabetes Impairs Cellular Cholesterol
 Efflux From ABCA1 to Small HDL Particles. *Circ Res.* 2020;127:1198-1210.

9. Yvan-Charvet L, Wang N and Tall AR. Role of HDL, ABCA1, and ABCG1
transporters in cholesterol efflux and immune responses. *Arteriosclerosis, thrombosis, and vascular biology*. 2010;30:139-43.

572 10. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ and 573 Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum 574 specimens with similar high-density lipoprotein cholesterol to remove cholesterol from 575 macrophages. *Arterioscler Thromb Vasc Biol.* 2010;30:796-801.

576 11. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K,
577 French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH and
578 Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and
579 atherosclerosis. *N Engl J Med*. 2011;364:127-35.

580 12. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, 581 Yuhanna IS, Rader DR, de Lemos JA and Shaul PW. HDL cholesterol efflux capacity 582 and incident cardiovascular events. *N Engl J Med*. 2014;371:2383-93.

- 583 13. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D,
 584 Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT,
 585 Wareham N and Rader DJ. Association of HDL cholesterol efflux capacity with incident
 586 coronary heart disease events: a prospective case-control study. *Lancet Diabetes*587 *Endocrinol.* 2015;3:507-13.
- 588 14. Kunnen S and Van Eck M. Lecithin:cholesterol acyltransferase: old friend or foe 589 in atherosclerosis? *Journal of Lipid Research*. 2012;53:1783-1799.
- 590 15. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen
 591 B, Hoyt RF, Jr., Marcovina S, Brewer HB, Jr. and Santamarina-Fojo S. High plasma
 592 HDL concentrations associated with enhanced atherosclerosis in transgenic mice
 593 overexpressing lecithin-cholesteryl acyltransferase. *Nat Med.* 1997;3:744-9.

Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH and Rader
DJ. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage
reverse cholesterol transport in vivo. *Circulation*. 2009;120:160-9.

597 17. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C,
598 Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M, Boscutti G, Cattin L, Gesualdo
599 L, Sampietro T, Vaudo G, Veglia F, Calandra S and Franceschini G. Functional lecithin:
600 cholesterol acyltransferase is not required for efficient atheroprotection in humans.
601 *Circulation*. 2009;120:628-35.

Kingwell BA, Nicholls SJ, Velkoska E, Didichenko SA, Duffy D, Korjian S and
Gibson CM. Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol
Efflux Capacity. *J Am Heart Assoc.* 2022;11:e024754.

605 19. Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO,

606 Therond P, Chapman MJ, Kontush A and Wright SD. Enhanced HDL Functionality in

607 Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL,

- 608 CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity. *Circ* 609 *Res.* 2016;119:751-63.
- 610 20. He Y, Song HD, Anantharamaiah GM, Palgunachari MN, Bornfeldt KE, Segrest
- JP and Heinecke JW. Apolipoprotein A1 Forms 5/5 and 5/4 Antiparallel Dimers in
 Human High-density Lipoprotein. *Mol Cell Proteomics*. 2019;18:854-864.
- 613 21. Tubb MR, Smith LE and Davidson WS. Purification of recombinant
- 614 apolipoproteins A-I and A-IV and efficient affinity tag cleavage by tobacco etch virus 615 protease. *J Lipid Res.* 2009;50:1497-504.
- 616 22. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW and Oda MN. The
- 617 interplay between size, morphology, stability, and functionality of high-density 618 lipoprotein subclasses. *Biochemistry*. 2008;47:4770-9.
- 619 23. Hutchins PM, Ronsein GE, Monette JS, Pamir N, Wimberger J, He Y,
- 620 Anantharamaiah GM, Kim DS, Ranchalis JE, Jarvik GP, Vaisar T and Heinecke JW.
- 621 Quantification of HDL particle concentration by calibrated ion mobility analysis. *Clin*
- 622 *Chem*. 2014;60:1393-401.
- 623 24. Caulfield MP, Li S, Lee G, Blanche PJ, Salameh WA, Benner WH, Reitz RE and
 624 Krauss RM. Direct determination of lipoprotein particle sizes and concentrations by ion
 625 mobility analysis. *Clin Chem.* 2008;54:1307-16.
- 626 25. Guha S, Li M, Tarlov MJ and Zachariah MR. Electrospray-differential mobility 627 analysis of bionanoparticles. *Trends Biotechnol*. 2012;30:291-300.
- Rinner O, Seebacher J, Walzthoeni T, Mueller LN, Beck M, Schmidt A, Mueller M
 and Aebersold R. Identification of cross-linked peptides from large sequence databases. *Nat Methods*. 2008;5:315-8.
- 631 27. Pourmousa M, Song HD, He Y, Heinecke JW, Segrest JP and Pastor RW.
 632 Tertiary structure of apolipoprotein A-I in nascent high-density lipoproteins. *Proc Natl*633 *Acad Sci U S A*. 2018;115:5163-5168.
- 634 28. Pan AC, Weinreich TM, Piana S and Shaw DE. Demonstrating an Order-of635 Magnitude Sampling Enhancement in Molecular Dynamics Simulations of Complex
- Protein Systems. *Journal of Chemical Theory and Computation*. 2016;12:1360-1367.
 Jo S, Kim T, Iyer VG and Im W. CHARMM-GUI: a web-based graphical user
- 638 interface for CHARMM. *J Comput Chem*. 2008;29:1859-65.
- 63930.Jones MK, Gu F, Catte A, Li L and Segrest JP. "Sticky" and "promiscuous", the640yin and yang of apolipoprotein A-I termini in discoidal high-density lipoproteins: a
- 641 combined computational-experimental approach. *Biochemistry*. 2011;50:2249-63.
- 642 31. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, Arca M, 643 Bon GB, Boscutti G, Busnach G, Frasca G, Gesualdo L, Gigante M, Lupattelli G,
- 644 Montali A, Pizzolitto S, Rabbone I, Rolleri M, Ruotolo G, Sampietro T, Sessa A, Vaudo
- 645 G, Cantafora A, Veglia F, Calandra S, Bertolini S and Franceschini G. The molecular
- basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive
 study of molecular and biochemical findings in 13 unrelated Italian families. *Arterioscler*
- 648 *Thromb Vasc Biol.* 2005;25:1972-8.
- 649 32. George RT, Abuhatzira L, Stoughton SM, Karathanasis SK, She D, Jin C, Buss
- 650 N, Bakker-Arkema R, Ongstad EL, Koren M and Hirshberg B. MEDI6012: Recombinant
- 651 Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density
- Lipoprotein Receptor-Mediated Reverse Cholesterol Transport. *J Am Heart Assoc.*
- 653 2021;10:e014572.

Mendez AJ, Oram JF and Bierman EL. Protein kinase C as a mediator of high
density lipoprotein receptor-dependent efflux of intracellular cholesterol. *J Biol Chem*.
1991;266:10104-11.

Segrest JP, Jones MK, Klon AE, Sheldahl CJ, Hellinger M, De Loof H and
Harvey SC. A detailed molecular belt model for apolipoprotein A-I in discoidal high
density lipoprotein. *J Biol Chem.* 1999;274:31755-8.

660 35. Mei X and Atkinson D. Crystal structure of C-terminal truncated apolipoprotein A-661 I reveals the assembly of high density lipoprotein (HDL) by dimerization. *J Biol Chem.* 662 2011;286:38570-82.

- 663 36. Davidson WS and Thompson TB. The Structure of Apolipoprotein A-I in High 664 Density Lipoproteins. *J Biol Chem*. 2007;282:22249-22253.
- 665 37. Thomas MJ, Bhat S and Sorci-Thomas MG. Three-dimensional models of HDL 666 apoA-I: implications for its assembly and function. *J Lipid Res*. 2008;49:1875-83.
- 667 38. Lima DB, Melchior JT, Morris J, Barbosa VC, Chamot-Rooke J, Fioramonte M,
- Souza T, Fischer JSG, Gozzo FC, Carvalho PC and Davidson WS. Characterization of
 homodimer interfaces with cross-linking mass spectrometry and isotopically labeled
 proteins. *Nat Protoc.* 2018;13:431-458.
- Forte T, Norum KR, Glomset JA and Nichols AV. Plasma lipoproteins in familial
 lecithin: cholesterol acyltransferase deficiency: structure of low and high density
 lipoproteins as revealed by elctron microscopy. *J Clin Invest.* 1971;50:1141-8.
- 40. Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G
 and Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency
 states. *J Lipid Res.* 2007;48:592-9.
- 676 States. *J Lipid Res.* 2007,46.592-9.
 677 41. Rosenson RS, Brewer HB, Jr., Chapman MJ, Fazio S, Hussain MM, Kontush A,
 678 Krauss RM, Otvos JD, Remaley AT and Schaefer EJ. HDL measures, particle
 679 heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular
- 680 events. Clin Chem. 2011;57:392-410.
- 42. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV and
 Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a
 review of secondary structure and function. *J Lipid Res.* 1992;33:141-66.
- 43. Shao B, Fu X, McDonald TO, Green PS, Uchida K, O'Brien KD, Oram JF and
 Heinecke JW. Acrolein impairs ATP binding cassette transporter A1-dependent
 cholesterol export from cells through site-specific modification of apolipoprotein A-I. J
- 687 Biol Chem. 2005;280:36386-96.
- 44. Mei X, Liu M, Herscovitz H and Atkinson D. Probing the C-terminal domain of
 lipid-free apoA-I demonstrates the vital role of the H10B sequence repeat in HDL
 formation. *J Lipid Res.* 2016;57:1507-17.
- 45. Vedhachalam C, Ghering AB, Davidson WS, Lund-Katz S, Rothblat GH and
 Phillips MC. ABCA1-induced cell surface binding sites for ApoA-I. *Arterioscler Thromb Vasc Biol.* 2007;27:1603-9.
- 46. Phillips MC. Is ABCA1 a lipid transfer protein? *J Lipid Res.* 2018;59:749-763.
 47. Segrest JP, Tang C, Song HD, Jones MK, Davidson WS, Aller SG and Heinecke
 JW. ABCA1 is an extracellular phospholipid translocase. *Nat Commun.* 2022;13:4812.
 48. Heinecke JW. Small HDL promotes cholesterol efflux by the ABCA1 pathway in
 macrophages: implications for therapies targeted to HDL. *Circ Res.* 2015;116:1101-3.

- 699 49. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN,
- 700 Wareham NJ, Kastelein JJ, Khaw KT and Boekholdt SM. Plasma levels of
- 701 lecithin:cholesterol acyltransferase and risk of future coronary artery disease in
- apparently healthy men and women: a prospective case-control analysis nested in the
 EPIC-Norfolk population study. *J Lipid Res.* 2010;51:416-21.
- 704 50. Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ and Group PS.
- 705 High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence
- of cardiovascular events: possible attenuation of cardioprotection associated with high
- HDL cholesterol. *Atherosclerosis*. 2010;208:537-42.
- 708
- 709

710	Table 4. Oliviaal above stavistics of the auchiests in the family study					
711	Characteristic	Controls (LCAT+/+) n=14	Heterozygotes (LCAT+/-) n=6	Homozygotes (LCAT-/-) n=4	<i>P</i> -value	
	Age (years)	49±20	54±16	47±18	0.81	
	Female/Male (n)	5/9	2/4	4/2		
	HDL-C (mg/dl)	71±9	40±11	9.2±6.1	.0005	
	LDL-C (mg/dl)	114±32	109±34	111±74	0.22	
	Triglycerides (mg/dl)	111±61	121±30	253±130	0.28	
	LCAT activity (nmol/mL per h)	42±9	20±13	0±0	<.0001	

P-values are from a mixed effect model and Tukey-Kramer post-tests.



715 Figure 1. Calibrated IMA (A) and CEC (B) of reconstituted HDLs (r-HDLs) prepared 716 by cholate dialysis and fractionation by high-resolution size exclusion

717 **chromatography**. (A) Representative IMA profiles of each size of r-HDL. To facilitate

718 comparison of the size distributions of the particles, the height of each r-HDL was set to

719 100%. The median sizes of the isolated particles were 8.0±0.2 nm, 8.8±0.1 nm, 9.6±0.1

nm, and 12.2±0.1 nm. (B) ABCA1-mediated cholesterol efflux capacity (CEC) using

equimolar concentrations of each size of r-HDL. Macrophage CEC and ABCA1 CEC of

serum HDL were quantified after a 4-h incubation with [³H]cholesterol-labeled J774

macrophages and BHK cells, without or with induction of ABCA1 expression with cAMP and mifepristone, respectively. Cholesterol efflux was calculated as the percentage of

radiolabel in the medium of the cells divided by the total radioactivity of the medium and

realized and realized as the difference in cholesterol efflux of cells with and without

induced expression of ABCA1. Results are representative of 5 independent experiments

with replicate analyses. *****P*<0.001, one-way ANOVA with Tukey-Kramer post-tests.

729



730

Figure 2. Contact maps of the intermolecular (Inter) and intramolecular (Intra) 731 732 APOA1 crosslinks detected by MS/MS in different sizes of r-HDL. Red regions and 733 green regions indicate the allowable distance of intermolecular and intramolecular 734 peptide contacts (15.1 Å), respectively, in a molecular dynamics simulation of the LL5/5 double-belt model of APOA1.²⁷ Crosslinks (o) between APOA1 residues are labeled. 735 736 Semi-quantitative estimates of the strengths of interactions between residues were 737 based on ion currents (Supplemental Material, Table S2), and they are indicated by 738 the colors of the circles (green, strong; yellow, medium; red, weak). Note that we 739 detected multiple intramolecular crosslinked peptides in the helix 8 to helix 10 region 740 and helix 9 to helix 10 region of the C-terminus of APOA1 of r-HDL-80 and r-HDL-90 741 particles, respectively, that are inconsistent with the classic double belt model. This 742 indicates that the C-terminus of APOA1 has increased conformational freedom and 743 does not assume the double belt conformation in that region. In contrast, the 744 intramolecular crosslinked peptides detected in that region of the two largest sizes of 745 HDL are consistent with the double belt model.

- 746
- 747





749

750 Figure 3. Comparison of stepwise conformational changes in APOA1 between r-751 HDL-120, r-HDL-100, r-HDL-90 and r-HDL-80 particles. Cartoon representations: 752 blue, N-terminal 43 (residues 1-43); green, pairwise helix 5 (residues 121-143); red, helix 10 (residues 220-243). Red arrowheads show the partially unfolded H7-H8 753 754 junctions. Blue arrowheads show the hairpin coil that allows helix 10 (H10A and H10B) to fold onto the POPC headgroup surface. A. Top view of r-HDL-120. B. Side view of r-755 HDL-120. C. Top view of r-HDL-100. D. Side view of r-HDL-100. E. Top view of r-HDL-756 757 90. F. Side view of r-HDL-90. G. Top view of r-HDL-80. H. Side view of r-HDL-80. Note that APOA1 in the two largest HDL particles (A-D; r-HDL-120 and -100) has a 758 759 conformation that is strongly lipid-associated and consistent with the classic double belt 760 model. In contrast, this structure is absent in both C-termini (H10A,B) of APOA1 in the 761 two smallest HDL particles (E-H; r-HDL-90 and -80).



762

763 Figure 4. Quantification of total HDL and HDL subspecies in LCAT-deficient (-/-), 764 LCAT-heterozygous (+/-), and control (+/+) subjects. (A) Representative size and 765 concentration profiles of HDL isolated from LCAT-deficient (-/-), LCAT-heterozygous 766 (+/-), and control (LCAT +/+) subjects. (B-F) HDL isolated by ultracentrifugation from 767 plasma (d=1.063-1.21 g/mL) was analyzed by calibrated IMA. The mean HDL subspecies sizes were: extra-small HDL (XS-HDL) 7.8 nm; small HDL (S-HDL) 8.4 nm; 768 medium HDL (M-HDL) 9.2 nm; large HDL (L-HDL) 10.9 nm. Arb, arbitrary units. HDL 769 770 isolated from plasma by ultracentrifugation was subjected to calibrated IMA. The sizes (mean, standard deviation) of the HDL subspecies were: extra-small HDL, 7.8±0.1 nm; 771 772 small HDL, 8.4±0.1 nm; medium HDL, 9.2±0.1 nm; large HDL, 10.9±0.2 nm. The 773 number of subjects was: LCAT+/+, n=14; LCAT+/-, n=6; LCAT-/-, n=6. P-value, oneway ANOVA with Tukey-Kramer post-tests. *** P<0.001, ** P<0.01, * P<0.05. 774

775



Figure 5. Calibrated IMA (A) and CEC (B) of HDL isolated from plasma of LCATdeficient (LCAT-/-) and control (XS-HDL, S-HDL, M-HDL, L-HDL) subjects. (A)

Representative IMA size profiles of isolated HDL. To facilitate comparison of the 778 particles' size distributions, the height of each isolated HDL fraction was set to 100%. 779 780 The diameters of the isolated HDLs of LCAT-/- subjects and control subjects were: 781 LCAT-/-, 7.8±0.1 nm; XS-HDL, 8.1±0.2 nm; S-HDL, 8.8±0.1 nm; M-HDL, 9.8±0.2 nm; L-HDL, 11.1±0.2 nm. Note that isolated XS-HDL is composed of both XS-HDL and S-HDL 782 783 particles. (B, C) ABCA1-mediated cholesterol efflux capacity (CEC) of HDL isolated 784 from LCAT-/- subjects and control subjects. Macrophage CEC and ABCA1 CEC of were 785 quantified with [³H]cholesterol-labeled J774 macrophages and baby hamster kidney 786 cells after a 4-h incubation. Expression of ABCA1 was induced with cAMP and 787 mifepristone, respectively. Cholesterol efflux was calculated as the percentage of radiolabel in the medium of the cells divided by the total radioactivity of the medium and 788 789 cells. CEC was quantified as the difference in cholesterol efflux of cells with and without induced expression of ABCA1. Isolated HDLs were included in the media of the cells at 790 791 equal particle concentrations. CEC of HDLs was normalized to CEC of cells exposed to

792 10 μg/mL of APOA1. *P*-value: one-way ANOVA with Tukey-Kramer post-tests.
 793 ****P*<0.001, ** *P*<0.01, * *P*<0.05.

794

795



796

797 Figure 6. ABCA1 CEC (A), HDL particle size distribution (B), free cholesterol (C) 798 and total cholesterol (D) content of control and LCAT-deficient plasma incubated 799 with LCAT. Control plasma (N=3) and LCAT- deficient plasma (N=3) were incubated 800 with and without recombinant human LCAT (rLCAT+ and rLCAT-; 50 µg/mL) for 1 h at 801 37°C. The LCAT reaction was stopped with 2 mM DTNB and cooling on ice. Control studies demonstrated that DTNB did not alter the CEC of plasma. DTNB was omitted 802 803 from plasma used to quantify cholesterol levels because it interfered with the enzymatic 804 assay. ABCA1 CEC of plasma was quantified using [³H]cholesterol-labeled BHK cells 805 as described in the legend to Fig. 5. P-values, ratio-t test.



806

807 Figure 7. The "flipped ends" model for the increased ABCA1 activity of small 808 HDLs. In large HDL particles, the C-termini of the APOA1 dimer are in antiparallel 809 helical bundles that are amphipathic and strongly associated with lipid. In small HDL 810 particles, the reduced surface area and high surface curvature force the C-termini off 811 the particles, increasing their mobility. The termini also are less lipid-associated 812 because APOA1 loses its amphipathic double belt structure. Decreased lipid 813 association and increased mobility of the C-termini (helices H8-10) promote the 814 engagement of APOA1 with the clasp domains of ABCA1, stimulating cholesterol 815 export from the cell. An alternative hypothesis is that the C-termini of APOA1

- 816 promote microsolubilization of phospholipids and cholesterol from phospholipid-rich
- 817 domains in the plasma membrane of cells (see Discussion).

818